





Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

Michaelis, M.; Rothweiler, F.; Barth, S.; Cinatl, J.; van Rikxoort, M.; Loeschmann, N.; Voges, Y.; Breitling, R.; von Deimling, A.; Roedel, F.

Published in: Cell death & disease

DOI: 10.1038/cddis.2011.129

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2011

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Loeschmann, N., Voges, Y., Breitling, R., von Deimling, A., Roedel, F., Weber, K., Fehse, B., Mack, E., Stiewe, T., Doerr, H. W., Speidel, D., Cinatl, J., & Cinatl jr., J. (2011). Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. *Cell death & disease*, *2*(12), [243]. https://doi.org/10.1038/cddis.2011.129

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverneamendment.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Suppl. Table 5. Sensitivity of UKF-NB-3^rNutlin^{10µM} cells transduced with a lentiviral vector encoding p53 shRNA (UKF-NB-3^rNutlin^{10µMp53-shRNA}) or scrambled shRNA (UKF-NB-3^rNutlin^{10µMscr-shRNA}) to anti-cancer drugs (indicated by the concentration that reduces cell viability by 50% (IC₅₀¹) indicated by MTT assay after a 5 day treatment period).

IC ₅₀ (ng/ml ¹)	
UKF-NB-3 ^r Nutlin ^{10µMp53-shRNA}	UKF-NB-3 ^r Nutlin ^{10µMscr-shRNA}
31.73 ± 5.22	33.81 ± 2.58
1.80 ± 0.19	1.97 ± 0.36
272.51 ± 14.62	289.58 ± 20.27
27.19 ± 2.39	29.67 ± 2.86
13.63 ± 2.33	12.48 ± 3.34
	$\begin{array}{c} \text{IC}_{50} \text{ (n}\\ \\ \text{UKF-NB-3}^{r}\text{Nutlin}^{10\mu\text{Mp53-shRNA}}\\ \\ 31.73 \pm 5.22\\ \\ 1.80 \pm 0.19\\ \\ 272.51 \pm 14.62\\ \\ 27.19 \pm 2.39\\ \\ 13.63 \pm 2.33 \end{array}$

 1 all concentrations are ng/mL except nutlin-3 concentrations that are μM